Home / Research Library / Updated efficacy and safety data from IMbrave150:...
🧬 Medicine & Biology OpenAlex

Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma

📅 December 11, 2021 👤 Ann‐Lii Cheng, Shukui Qin, Masafumi Ikeda et al. 📖 Journal of Hepatology 📊 1,612 citations

🤖 Plain-English Summary

This research explores Updated efficacy and safety data from IMbrave150: Atezolizum..., contributing new insights to the field of Medicine & Biology.

🔑 Key Findings

  • Research demonstrates significant advances in patient outcome data
  • Study provides new evidence regarding clinical efficacy results
  • Findings open new directions for biological mechanism insights

💡 Why This Matters

Understanding this could lead to better treatments, improved diagnostics, or a deeper grasp of how the human body works — benefiting patient care globally.

Read the full paper
Access the original peer-reviewed research via OpenAlex.

View on DOI ↗

📋 Article Details

Category 🧬 Medicine & Biology
Published Dec 11, 2021
Journal Journal of Hepatology
Authors Ann‐Lii Cheng, Shukui Qin, Masafumi Ikeda, Peter R. Galle, Michel Ducreux
DOI 10.1016/j.jhep.2021.11.030
Citations 1,612
Source OpenAlex

More 🧬 Medicine & Biology Research